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Abstract 
Background: In Zambia, malaria is one of the leading causes of morbidity and mortality, especially among under 
five children and pregnant women. For the latter, the World Health Organization recommends the use of artemisinin‑
based combination therapy (ACT) in the second and third trimester of pregnancy. In a context of limited information 
on ACT, the safety and efficacy of three combinations, namely artemether–lumefantrine (AL), mefloquine–artesunate 
(MQAS) and dihydroartemisinin–piperaquine (DHAPQ) were assessed in pregnant women with malaria.
Methods: The trial was carried out between July 2010 and August 2013 in Nchelenge district, Luapula Province, an 
area of high transmission, as part of a multi‑centre trial. Women in the second or third trimester of pregnancy and 
with malaria were recruited and randomized to one of the three study arms. Women were actively followed up for 
63 days, and then at delivery and 1 year post‑delivery.
Results: Nine hundred pregnant women were included, 300 per arm. PCR‑adjusted treatment failure was 4.7% 
(12/258) (95% CI 2.7–8.0) for AL, 1.3% (3/235) (95% CI 0.4–3.7) for MQAS and 0.8% (2/236) (95% CI 0.2–3.0) for DHAPQ, 
with significant risk difference between AL and DHAPQ (p = 0.01) and between AL and MQAS (p = 0.03) treatments. 
Re‑infections during follow up were more frequent in the AL (HR: 4.71; 95% CI 3.10–7.2; p < 0.01) and MQAS (HR: 1.59; 
95% CI 1.02–2.46; p = 0.04) arms compared to the DHAPQ arm. PCR‑adjusted treatment failure was significantly asso‑
ciated with women under 20 years [Hazard Ratio (HR) 5.35 (95% CI 1.07–26.73; p = 0.04)] and higher malaria parasite 
density [3.23 (95% CI 1.03–10.10; p = 0.04)], and still women under 20 years [1.78, (95% CI 1.26–2.52; p < 0.01)] had a 
significantly higher risk of re‑infection. The three treatments were generally well tolerated. Dizziness, nausea, vomiting, 
headache and asthenia as adverse events (AEs) were more common in MQAS than in AL or DHAPQ (p < 0.001). Birth 
outcomes were not significantly different between treatment arms.
Conclusion: As new infections can be prevented by a long acting partner drug to the artemisinins, DHAPQ should 
be preferred in places as Nchelenge district where transmission is intense while in areas of low transmission intensity 
AL or MQAS may be used.
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Background
Malaria is a poverty-related disease and a major public 
health problem in many sub-Saharan African countries 
where over 90% of the cases worldwide are found. Preg-
nant women and children are at higher risk of malaria 
infection and of developing serious complications related 
to the disease. Malaria in pregnancy is associated with 
higher risk of maternal anaemia, low birth weight, spon-
taneous abortion, stillbirths and maternal mortality 
[1–3].
There are few treatments with known safety and effi-
cacy for the treatment of malaria in pregnancy. Some 
anti-malarials known to be efficacious e.g. quinine, are 
not well tolerated, resulting in poor compliance and 
higher risk of treatment failures [4]. For other treat-
ments, there are insufficient data as pregnant women are 
systematically excluded from treatment efficacy studies. 
Therefore, pregnant women lack proven effective and 
safe anti-malarial therapies [5]. In such context of lim-
ited information, and weighing risks and benefits, the 
World Health Organization (WHO) allows the use of 
artemisinin-based combination therapy (ACT) during 
the second and third trimester of pregnancy [1].
To confirm this expert opinion, we assessed the safety 
and efficacy of three artemisinin-based combinations, 
namely mefloquine–artesunate (MQAS), dihydroarte-
misinin–piperaquine (DHA–PQ) and artemether–lume-
fantrine (AL), in pregnant women in the second or third 
trimester with a confirmed Plasmodium falciparum 
malaria infection. This study was part of a multi-centre 
trial carried out also in Burkina Faso, Ghana and Malawi. 
Each site tested 3 ACT medicines so that each country 
dataset could be analysed separately [6] and give detailed 
site specific data. This paper reports results collected in 
the Zambian site, Nchelenge, Luapula Province. Knowing 
that anti-malarial drug’s efficacy depends not only on the 
parasite susceptibility to the drug and on its blood con-
centration but also on the host’s immunity which may be 
affected by factors such as pregnancy itself, age, parasite 
density and malaria transmission intensity, the impact of 
these factors on the treatment outcome were assessed [7, 
8]. The results of this study provide the national policy 
makers the information for a wider and alternative choice 
of treatments to be used during pregnancy.
Methods
The trial was conducted between June 2010 and August 
2013 in Nchelenge district in Luapula Province, Zambia; 
one of the provinces where malaria prevalence is higher 
than the national average (32.1% vs 14.9% in 2012) [9]. 
Nchelenge district is located in the northern part of the 
province on the swampy shores of Lake Mweru, bor-
ders with the Democratic Republic of Congo (DRC) 
and has an estimated population of 178,000 inhabitants, 
mostly peasant farmers and/or fishermen. The district 
has three seasons: cool dry winter, hot dry and rainy sea-
son. Malaria transmission is perennial because of the 
presence of Anopheles funestus during the dry season 
and Anopheles gambiae in the wet season [10]. In 2012-
2013, the entomological inoculation rate (EIR) was esti-
mated at 70 infective bites/person/year [11], and annual 
malaria incidence at more than 700/1000 person years 
in the general population and more than 1900/1000 per-
son years among under-five children [12]. The study pro-
tocol of this trial is been described in detail elsewhere 
[13]. Briefly, pregnant women aged at least 15  years, in 
the second and third trimester, with Hb  ≥7  g/dL, HIV 
negative, a P. falciparum mono-infection of any density 
and irrespective of having symptoms (excluding illness 
at time of screening that required hospitalization such 
as severe malaria) were recruited into the trial and ran-
domized to one of the following treatments: artemether–
lumefantrine (AL), mefloquine–artesunate (MQAS) and 
dihydroartemisinin–piperaquine (DHA–PQ) using a ran-
domization list provided of 300 participants in each arm. 
Sealed envelopes labeled with patient’s unique code and 
containing treatment allocation were provided according 
to randomization list. A woman was defined as sympto-
matic if any of the following were present: fever (tempera-
ture >37.5 °C) at baseline with parasitaemia (any density); 
parasite count >2000/µL, regardless of symptoms; at least 
3 or more of the following symptoms: fever in the past 
24 h, weakness/fatigue; muscle and/or joint aches, head-
ache, convulsion, with parasitaemia of any density). Ges-
tational age was estimated by symphysio-fundal height 
and then confirmed by obstetric ultrasound, including 
the fetal viability assessment [14, 15]. A blood sample of 
about 5 mL was collected before treatment for the assess-
ment of haematological and biochemistry parameters. All 
study drugs were given on days 0, 1 and 2 under direct 
observation and according to the manufacturer’s recom-
mendations  (Eurartesim® from Sigma-Tau Industrie Far-
maceutiche Riunite S.p.A., 40  mg of dihydroartemisinin 
and 320 mg of piperaquine phosphate per tablet, 3 tab-
lets once per day over 3  days; mefloquine–artesunate 
from Far-Manguinhos Ministério da Saúde-Fundação 
Oswaldo Cruzm, 100 mg artesunate and 220 mg meflo-
quine per tablet at 3 tablets once per day over 3  days; 
 Coartem® from Novartis Pharma AG, 20 mg artemether 
and 120 mg lumefantrine per tablet at 4 tablets twice per 
day over 3 days). After completing the 3-day treatment, 
patients were asked to return to the clinic for follow up 
visits on day 3, 7 and then once every week until day 63. 
At each visit, a medical history, and current clinical signs 
and symptoms were collected, including information 
on any adverse events (AE), a blood sample for malaria 
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smears and dried blood spots (DBS) for later genotyping, 
for full blood counts (days 7, 14, 28 and 63 only) and for 
total bilirubin, alanine aminotransferase (ALAT) and cre-
atinine (days 7 and 14 only). Rescue treatment (Quinine) 
for recurrent infections was according to local national 
guidelines [16]. (In Zambia, AL is used for treatment of 
uncomplicated malaria in second and third trimester of 
pregnancy). At the end of the active follow-up period, 
women were asked to continue with the antenatal clinic 
monthly or when they felt unwell until delivery. Recur-
rent malaria episodes after day 63 were treated with 
quinine.
Giemsa-stained thick and thin blood films were read 
independently by two readers, followed by a third reader 
in case of significant discrepancy. Parasite density was 
estimated by counting the number of asexual parasites 
per 200 white blood cells (WBCs) assuming a WBC 
count of 8000/µL. Total bilirubin, ALAT and creatinine 
were measured using Flexor Junior biochemistry ana-
lyzer. Full blood count was obtained using the Sysmex 
XT-2000i haematology analyzer. Haemoglobin (Hb) was 
measured using Hemocue (Angelholm, Sweden). For 
polymerase chain reaction (PCR) analysis, DBS were pre-
pared on filter paper (Whatman 3MM), and were subse-
quently transported to the Institute of Tropical Medicine 
(ITM), Antwerp, Belgium, where centralized genotyp-
ing (GluRP, MSP2 and MSP1) was conducted [17]. Sam-
ples that failed to produce a result were classified as 
indeterminate.
Consent was obtained in all cases from study partici-
pants and/or legal representative for those between 15 
and 17 years old. The study was approved by the Institu-
tional Review Board of the ITM and the Ethics Commit-
tee of the Antwerp University Hospital. In addition, the 
study was also approved by Tropical Diseases Research 
Centre (TDRC) Ethics Review Committee, the Zambia 
Medicines Regulatory Authority and Zambia Ministry 
of Health. The trial was registered at clinicaltrials.gov 
(NCT00852423).
The primary endpoints were the PCR-adjusted cure 
rates at day 63 and the safety outcomes as described else-
where [13]. AEs and serious AEs (SAEs) were recorded and 
monitored regularly throughout the study by an independ-
ent Data and Safety Monitoring Board (DSMB). Secondary 
endpoints were PCR-unadjusted cure rates at day 63, PCR 
adjusted and unadjusted time to treatment failure, asexual 
parasite clearance [18], gametocytaemia (prevalence and 
density) and Hb changes during follow up.
The study was designed to show that all 3 treatments 
had similar (PCR-adjusted) cure rates (within 5% differ-
ence), with 95% power for each of the 3 pair-wise com-
parisons and 80% power for the combined hypothesis 
that all treatments were therapeutically equivalent [13].
Data were captured into an electronic clinical record 
form (e-CRF) developed in MACRO (InferMed©). A 
statistical analysis plan was pre-specified before the 
database lock. For the primary outcome, three analy-
sis populations were used: (1) per-protocol (PP), (2) 
intention-to-treat (ITT) that excluded lost to follow-up 
(LTFU)/withdrawals and missing/indeterminate PCR 
results, and (3) ITT with multiple imputations of LTFU/
withdrawals and missing/indeterminate PCR results. 
The PP analysis was considered as the primary analysis 
approach. Major protocol violators, defined prior to anal-
ysis, were excluded from the PP analysis.
PCR-adjusted treatment failure rate between pair-wise 
treatment groups was compared using a Chi square test. 
The 95% exact confidence intervals for the difference in 
failure rates were determined. If the difference in true 
(PCR adjusted) failure rates was less than 5%, treatments 
were considered therapeutically equivalent. Briefly, risk 
difference was computed for the following groups: AL 
and DHAPQ; AL and MQAS; and MQAS and DHAPQ. 
The 95% confidence interval for a proportion was calcu-
lated using the Wilson score method. Baseline variables 
to be included in the Cox-regression model to compute 
the adjusted hazards of re-infection (new infection) and 
recrudescence were selected using the log-rank test for 
equality across strata. The covariates were included if 
the p value was 0.25 or less except study treatment dos-
age. The starting covariates were treatment, sympto-
matic malaria, parasite density, maternal age, gravidity, 
anaemia, study treatment dosage, gestational age, hae-
matological and biochemical parameters. Covariates in 
the multivariable model that were not statistically sig-
nificant (>0.05) were dropped off except where literature 
shows them as important variables [gravidity and ges-
tational age (dropped for new infection)] to have in the 
final model. The proportion hazard assumptions for the 
Cox-regression model were evaluated using graphical 
approach [19].
The hematological and biochemistry profiles by day of 
follow-up were assessed using box-plots plotted at each 
time point. Differences in these parameters between 
treatment arms at each day of follow-up were assessed 
using Kruskal–Wallis test.
Firth logistic regression was used to assess impact of 
placental malaria (categorized as placental malaria or 
no infection) on birth outcomes (still birth, miscarriage, 
premature live delivery, intrauterine fetal death and term 
live birth) for separation and ‘empty cells’ in the model. 
A “stillbirth” was defined as a baby born dead after 
24  weeks gestation; a baby born dead before 24  weeks 
gestation or during the 24th week was considered a “mis-
carriage”. “Preterm live born” was defined as a delivery 
before 37 weeks of gestation following echography. This 
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was calculated as date of delivery minus date of echogra-
phy (in weeks) plus gestational age determined through 
echography. Or based on the Ballard score which deter-
mines gestational age based on the sum of neuromus-
cular and physical scores [20]. A neonate with a score 
of 30 or lower was labeled “preterm” using this method. 
Logistic regression was used to assess impact of placental 
malaria (categorized as placental malaria or no infection) 
on birth weight. It was also used to assess risk factors for 
malaria. Placental malaria was classified as acute infec-
tion; chronic infection; past infection or no infection 
and analysed as binary outcome, placental malaria or no 
infection. For safety, all individuals having received at 
least one treatment dose were included and analysed in 
terms of proportions with Chi square test for the differ-
ence. Delivery related AEs, caesarean sections or reasons 
for caesarean sections and pregnancy outcomes were not 
included in the AE report. Also SAEs which were preg-
nancy related were excluded.
Results
A total of 1722 pregnant women were screened for 
malaria infection, regardless of symptoms. Out of these, 
900 met the inclusion criteria and were randomized to 
one of the three study arms: 300 to AL, 300 to MQAS 
and 300 to DHAPQ. The ITT analysis included 900 preg-
nant women. The PP analysis included 729 women, i.e. 
258 in the AL, 235 in the MQAS and 236 in DHAPQ 
arms (Fig.  1). The main reasons for exclusion from the 
PP analysis were lost to follow-up and withdrawals. The 
baseline characteristics (age, gravidity, parasite density, 
Hb, symptoms) of the excluded patients were similar to 
those included in the PP analysis.
Baseline characteristics were similar between treat-
ment arms (Table  1); all gravidities were equally rep-
resented and the median gestational age by obstetric 
ultrasound (echography) was 25.0  weeks [IQR: 20.5–
29.0] and similar between the treatment arms. The 
median parasite density was 1540/µL (IQR: 480–4540) 
and similar between the treatment arms [AL 1360/
µL (IQR: 480–4280), MQAS 1610/µL (IQR: 540–4340) 
and DHAPQ 1640/µL (IQR: 520–4880)]; over 40% of 
women had a parasite density ≥2000/μL and 49% were 
symptomatic.
The gametocyte prevalence at baseline was low, 
2.3% (95% CI 1.1–4.7) in AL, 1.3% (95% CI 0.5–3.4) in 
DHAPQ and 0% (95% CI 0.0–1.3) in MQAS. The range of 
the gametocyte density, if present, was 40–440 gameto-
cytes/µL. Gametocyte carriage remained low during the 
follow-up period and only appeared in AL (4/297; 1.3%) 
and DHAPQ (6/292; 2.1%) arms and none in MQAS. Use 
of preventive measures, i.e. ITN and IPTp, at recruitment 
was low (Table 1).
In the PP analysis, the graphs for the global propor-
tional hazards (PH) assumptions testing for treatment 
failure adjusted for several variables (treatment, anae-
mia, gestational age, gravidity, parasite density, mater-
nal age and malaria symptoms at baseline) were roughly 
parallel and met the PH assumptions. The day 63 PCR-
adjusted treatment failure rate was 4.7% (12/258) (95% CI 
2.7–8.0) for AL, 1.3% (3/235) (95% CI 0.4–3.7) for MQAS 
and 0.8% (2/236) (95% CI 0.2–3.0) for DHAPQ (Table 2), 
with significant risk difference between AL and DHAPQ 
(p = 0.01) and between AL and MQAS (p = 0.03) treat-
ments. Figure  2 which shows the time to PCR adjusted 
and unadjusted treatment failure confirms this differ-
ence. Figure 3 presents the risk difference computed for 
the pairwise comparisons conducted for PCR-adjusted 
and unadjusted treatment success rates at day 63. AL 
showed somewhat higher (about 3%) PCR-adjusted treat-
ment failures. Therapeutic equivalence could be shown 
for MQAS and DHAPQ but not for AL as compared 
to the other 2 treatments. The ITT analysis gave simi-
lar results (Table  2). When considering recrudescence, 
i.e. treatment failure due to the reappearance of the 
same strain as identified by PCR analysis, its hazard was 
higher in patients treated with AL than in those treated 
with DHAPQ (HR: 10.47; 95% CI 2.18–50.19; p  <  0.01) 
although the estimates were unstable probably due to the 
small or low number of observations. The hazard was not 
significantly different in the MQAS than in the DHAPQ 
arm (HR: 1.56; 95% CI 0.26–9.38; p = 0.63) (Table 3). The 
hazard of treatment failure was higher in younger women 
than in those over 20 years (HR: 5.07; 95% CI 1.01–25.43; 
p =  0.05). Higher parasite density at baseline was asso-
ciated with a higher hazard of PCR-adjusted treatment 
failure (HR: 3.35; 95% CI 1.07–10.45; p = 0.04) (Table 3). 
New infections were more frequent in the AL (HR: 4.71; 
95% CI 3.10–7.15; p < 0.01) and MQAS (HR: 1.59; 95% CI 
1.02–2.46; p = 0.04) arms compared to the DHAPQ arm. 
The risk of re-infections was higher in women between 
15 and 20  years (HR: 1.78; 95% CI 1.26–2.52; p  <  0.01) 
than in women older than 20  years. Anaemic mothers 
had a higher hazard of new infection during follow up 
(HR: 1.56; 95% CI 1.05–2.32; p = 0.03). Similarly, moth-
ers with higher parasite density a higher hazard of new 
infection (HR: 1.46; 95% CI 1.09–1.94; p = 0.01). All the 
other risk factors analysed were not significantly associ-
ated with new infection (Table 3).
Placental malaria infection (acute and chronic) was 
similar between the treatment arms (p = 0.47) (Table 2). 
Treatment allocation, AL and MQAS (DHAPQ as 
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reference group), was not significantly related to pla-
cental malaria (OR 1.22; 95% CI 0.45–3.31 and OR 0.76; 
95% CI 0.34–1.72, respectively) (p = 0.58). Women with 
recrudescence and new infections were at higher risk of 
placental malaria (OR 4.46; 95% CI 1.01–19.70; p = 0.05). 
Placental malaria was significantly higher in women 
between 15 and 20  years (OR 4.56; 95% CI 1.48–14.04; 
p = 0.01) than in women older than 25 years. Placental 
malaria was significantly associated with low birth weight 
(<2500 g) (OR 4.37; 95% CI 1.04–18.39; p = 0.04) but not 
Fig. 1 Trial flow chart of the PREGACT trial at Nchelenge, Zambia (2010–2014)
Page 6 of 13Nambozi et al. Malar J  (2017) 16:199 
with adverse birth outcomes (stillbirth, preterm, miscar-
riage, intrauterine fetal death). (OR 5.47; 95% CI 0.33–
90.62; p = 0.24).
The study drugs were generally safe with a total of 
7 SAEs for mother. A woman treated with MQAS died 
41 days after treatment, probably because of meningitis. 
There were three SAEs in DHAPQ [low haemoglobin, 
measles and sickle cell mother in haemolytic crisis (vaso-
occlusive)]. An additional SAE in the MQAS arm, severe 
vomiting, was considered related to study treatment and 
recovered completely. The other two in MQAS were asth-
matic attack and pneumonia. They all recovered.
The proportion of women with AEs in each treat-
ment arm (82.7% in AL, 84.9% in MQAS and 79.3% in 
DHAPQ) were not significantly different (p  =  0.19) 
(Table  4). The drug-related AEs (dizziness, nausea, 
headache, vomiting and asthenia) were more common 
in the MQAS arm (67.9%; 95% CI 62.4–72.9) than the 
AL (12.7%; 95% CI 9.3–16.9) and DHAPQ arms (23.3%; 
95% CI 18.9–23.4) (p < 0.01). There were significant dif-
ferences in median Hb at day 7 between AL (10.1 g/dL) 
versus MQAS (9.9 g/dL)), p = 0.01; and AL vs DHAPQ 
(9.9 g/dL), p = 0.04; and at day 63 between AL (10.7 g/
dL) vs DHAPQ (11.0  g/dL), p  =  0.01 (Fig.  4). There 
were no significant differences in systolic and diastolic 
blood pressures between the treatment arms (p =  0.07 
and p  =  0.20 respectively). The median biochemical 
(creatinine, ALAT and bilirubin) safety values between 
treatment groups did not differ significantly during 
the follow-up period (p =  0.69, p =  0.92 and p =  0.88 
respectively) (Fig. 4). 
There were 21 stillbirths: 8 (2.7%) in AL, 3 (1.0%) in 
MQAS and 10 (3.3%) in the DHAPQ arms and three mis-
carriages (two in MQAS, one in DHAPQ arms, and none 
in the AL arm). The preterm delivery was 4.3% in AL, 
2.0% in MQAS and 3.3% in the DHAPQ arm. There were 
15 congenital malformations [3 cleft lip and palate, one 
club foot, one ear tag, 6 polydactyl, one syndactyl, one 
umbilical hernia, one depression on parietal bone, one 
tongue tie) observed (4 (1.3%) in each of DHAPQ and 
MQAS arms and 7 (2.3%) in AL arm] with no significant 
difference between the arms (p = 0.54).
Table 1 Baseline characteristics of pregnant women with malaria episode Nchelenge, Zambia (2010–2014)
a At least 3 or more of the following symptoms: fever in the past 24 h, weakness/fatigue; muscle and/or joint aches, headache, convulsion, with parasitaemia of any 
density
b 2nd Trimester were patients ≤24 weeks gestation and 3rd trimester >24 weeks gestation
c Women were provided with ITN at study start
AL (N = 300) MQAS (N = 300) DHAPQ (N = 300)
Age (years): median (IQR) 20 (18–24) 19 (18–24) 20 (18–24)
Symptomatic malaria (%) 46.0 48.7 52.7
 Fever (temperature ≥ 37.5 °C) (%) 2.0 3.3 3.7
 Parasite density >2000/µL (%) 41.0 42.7 45.7
 At least 3  symptomsa (%) 11.0 12.3 12.0
Gametocytes present (%) 2.3 0 1.3
Parasite density (/µL): median (IQR) 1360 (480–4280) 1610 (540–4340) 1640 (520–4880)
Haemoglobin (g/dL): median (IQR) 10.0 (9.1–11.0) 10.0 (9.0–10.9) 10.0 (9.2–10.9)
Gravidity
 1st Pregnancy (%) 33.3 35.7 31.3
 2nd Pregnancy (%) 30.3 30.3 32.0
 3rd Pregnancy or more (%) 36.3 34.0 36.7
Gestational  ageb
 2nd Trimester (%) 50.0 50.0 43.7
 3rd Trimester (%) 50.0 50.0 56.3
Bed net used before study entry (%) 30.7 28.7 27.3
ITN used before study  entryc (%) 25.3 21.0 22.7
 IPT use (before day 0) (%) 9.7 7.0 11.7
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Table 2 Malaria treatment outcome of pregnant women with malaria episode in Nchelenge, Zambia (2010–2014)
LTFU Lost to follow-up; PP per-protocol; ITT intention-to-treat
a Early Treatment Failure (ETF) defined as one of the following: (i) development of danger signs or severe malaria or worsening of clinical conditions on day 0, day 
1, day 2 or day 3, in the presence of parasitaemia, (ii) parasitaemia on day 3 ≥count on day 0, (iii) parasitaemia on day 3 and fever (axillary temperature ≥37.5 °C). 
Late clinical failure (LCF) defined as (i) development of danger signs or severe malaria or worsening of clinical conditions on any day after day 3 in the presence 
of parasitaemia, without previously meeting any of the criteria of Early Treatment Failure or (i) presence of parasitaemia and fever on any day after day 3, without 
having previously meet the criteria of ETF. Late parasitological failure (LCF) defined as presence of parasitaemia on any day from day 4 onwards and axillary 
temperature <37.5 °C, without previously meeting any of the criteria of ETF or LCF. Adequate clinical and parasitological response (ACPR) defined as absence of 
parasitaemia at the end of the follow up period (day 63), irrespective of axillary temperature without previously meeting any of the criteria of early and late treatment 
failure. In the PCR-adjusted estimates, patients with late asexual parasite reappearance (with or without fever) are considered ACPR if the PCR analysis shows a new 
infection rather than a recrudescence. Placental malaria classified as: acute infection (parasite present, malaria pigment absent); chronic infection (parasites and 
malaria pigment present); past infection (no parasite but pigment present); no infection (both parasites and malaria pigment absent)
AL (N = 300) MQAS (N = 300) DHAPQ (N = 300)
Efficacy outcomes, n (%)
Early treatment  failurea 0 0 1
Late clinical and parasitological treatment  failurea 126 60 36
 Recrudescence 12 5 2
 New infection 114 55 34
Adequate clinical and parasitological  responsea 132 175 199
Cannot be determined 42 65 64
 Did not meet inclusion/exclusion criteria/missing 8 17 8
 Treatment violations 1 0 1
 No PCR sample 0 3 4
 LTFU/died/withdrawn 33 45 51
Treatment failure rate % (95% CI)
PP‑analysis: PCR‑unadjusted 48.4 (42.4–54.5) 23.9 (19.0–29.8) 16.3 (12.1–21.4)
PP‑analysis: PCR‑adjusted 4.7 (2.7–8.0) 1.3 (0.4–3.7) 0.8 (0.2–3.0)
ITT‑analysis: PCR‑unadjusted 47.6 (41.7–53.5) 25.1 (20.2–30.8) 16.5 (12.4–21.6)
ITT‑analysis: PCR‑adjusted 4.9 (2.9–8.2) 2.0 (0.9–4.6) 1.2 (0.4–3.5)
Placental malaria N = 235 N = 228 N = 227
 Acute infection, n (%) 3 (1.3) 2 (0.9) 0 (0.0)
 Chronic infection, n (%) 75 (31.9) 70 (30.7) 67 (29.5)
 Past infection, n (%) 148 (63.0) 139 (61.0) 146 (64.3)
 No infection, n (%) 9 (3.8) 17 (7.5) 14 (6.2)
Fig. 2 Time to PCR adjusted and unadjusted treatment failure in Zambian leg of PREGACT study in Nchelenge, Zambia (2010–2014)
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Discussion
With the range of 0.8–4.7% recrudescences, the three 
artemisinin-based combinations used for the treatment 
of uncomplicated malaria in the second and third tri-
mester of pregnancy were efficacious, in an area of high 
endemicity in Nchelenge district, Zambia. Therapeutic 
equivalence could be shown for MQAS and DHAPQ but 
not for AL as compared to the other two treatments. In 
Nchelenge Zambia, there were significantly more treat-
ment failures in the AL arm compared to the other two 
arms, though AL efficacy was still above the 90% cure 
threshold recommended by WHO for adopting new anti-
malarial treatments as policy [21]. In Uganda, in an area 
with malaria transmission as high as that in Nchelenge, 
AL administered to pregnant women was also extremely 
efficacious, with even less treatment failures (0.7%) than 
in this trial [22].
In Zambia, ACT has been shown to have excellent cure 
rates among children and adults [23, 24]. Their efficacy, 
determined by the drug partnering an artemisinin deriva-
tive, namely mefloquine, lumefantrine, and piperaquine 
for the treatment tested in this study, usually exceeds 95% 
[25]. However, there have been reports pointing to the 
effect of the physiological changes during pregnancy, e.g. 
as increased volume of distribution, reduced gut motil-
ity, possibly altering drug disposition and metabolism, 
and thus leading to incorrect dosing [26–28]. This does 
not seem to apply to the results observed in Nchelenge 
as treatment efficacy was very high, possibly due to the 
underlying anti-malarial immunity in the Nchelenge dis-
trict population, including pregnant women, due to the 
intense malaria transmission and high exposure to infec-
tion. The importance of pre-existing immunity on the 
therapeutic response is also supported by the associa-
tion between treatment failure (both new infections and 
recrudescences) and young age [29]. Also transmission 
intensity may not influence the risk difference between 
treatments but may influence individual failure rates.
Pregnant women have an increased susceptibility to 
malaria, and this susceptibility is greatest in the first preg-
nancy (primigravidae) [30]. The decreasing prevalence 
and intensity of infection in successive pregnancies mir-
rors the acquisition of antibody immunity to the variant 
surface antigens, expressed on the parasitized red blood 
cells infecting the placenta. Antibodies titres against 
VSA-PAM are associated to clinical outcomes [31, 32] 
and opsonizing antibodies that allow phagocytic clear-
ance of infected erythrocytes are associated with a bet-
ter treatment outcome in pregnant women [33]. Results 
from Nchelenge and other studies suggest that antibodies 
to VSA-PAM might have important roles in determining 
both pregnancy outcomes and the effectiveness of anti-
malarial drugs in pregnancy. Other factors such as cel-
lular immunity, cytokines, and hormonal changes might 
also influence outcomes in pregnancy [29] and also affect 
treatment outcome.
Fig. 3 Pair‑wise comparisons for PCR adjusted and unadjusted ACPR at days 63 (PP population). Nchelenge, Zambia (2010–2014) (95% CI)
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In Nchelenge, pregnant women treated with AL had 
a higher risk of new infection than the other two treat-
ments. This is probably due to the shorter post-treatment 
prophylaxis offered by lumefantrine which is eliminated 
more rapidly [34] than piperaquine [35]. When the arte-
misinin component is rapidly eliminated, a new infec-
tion would encounter only the partner drug and this may 
explain the association between the risk of new infec-
tion and treatment given. It indirectly confirms that the 
distinction between recrudescence and new infection 
and genotyping is reasonably reliable. Considering that 
Nchelenge women who experienced a new infection 
during follow up had a higher risk of acute or chronic 
placenta malaria, both conditions associated to the deliv-
ery of low birth weight babies, a longer post-treatment 
prophylaxis would be extremely important in this area of 
intense malaria transmission. Therefore, DHAPQ could 
be preferentially chosen for such conditions, while AL 
could be used where transmission is low.
Recrudescence may easily occur in the context of 
emergence or spread of parasite resistance to a given 
anti-malarial when the partially efficacious anti-malarial 
may fail to clear the resistant strain or simply select for 
mutant parasites. In Zambia, artemisinin resistance has 
not been reported yet. Recrudescence can be caused by 
the parasites surviving the effect of a shorter-acting ACT 
[6], in this case AL. Low study drug dosage may play an 
important role in recrudescence in the AL group as the 
point estimate indicates low study drug dosage suggests 
a double independent risk for recrudescence. However, 
the power of the study was to assume a clear associa-
tion. Besides parasite sensitivity to drug and the level of 
the concentration of the drug in the blood, host immu-
nity and parasite density at presentation contributes to 
positive treatment outcome. Immunity can be affected 
by different factors, including age, body temperature, 
pregnancy and parity [29, 36]. The Nchelenge study has 
shown that younger women and high malaria parasite 
density at baseline are associated with recrudescence and 
could not demonstrate a significant association between 
treatment failure and parity.
Other studies have shown that high parasite density at 
presentation is associated with treatment failure [30–33, 
36–38] and that age, temperature and parasite density are 
predictors of anti-malarial treatment failure [36].
The three artemisinin-based combinations tested are 
generally safe in second and third trimester of preg-
nancy in Zambia. Patients on MQAS had higher rates of 
treatment-related AE. Dizziness was the most common, 
followed by vomiting and weakness. Dizziness has been 
reported even in other studies as related to MQ treat-
ment [39]. On the pregnancy outcomes, there was no 
significant difference between treatments for stillbirths, 
miscarriages, congenital malformations and prematurity, 
a finding similar to those of other studies on AL [22, 40, 
41], mefloquine [5] and DHAPQ [42].
This trial was done in an area where the majority of the 
population practice farming and fishing as a source of 
livelihood and they migrate to farming areas for a con-
siderable period [43], possibly explaining the relatively 
high number of lost-to-follow-ups and withdrawals. 
Table 3 Risk factors associated with  recrudescence 
and  new infection after  anti-malarial treatment in  preg-
nant women in Nchelenge, Zambia (2010–2014)
a p value of the joint effect of treatment
Hazard ratio 95% CI p value
Risk factors associated with recrudescence
Treatment
 AL 10.47 2.18–50.19
 MQAS 1.56 0.26–9.38
 DHAPQ 1 1 (reference) <0.01a
Maternal age (15–19 years) 5.07 1.01–25.43 0.05
Gestational age
 2nd Trimester 2.35 0.76–7.40
 3rd Trimester 1 1 (reference) 0.14
Gravidity
 Primigravidae 1.44 0.51–4.38
 Multigravidae 1 1 (reference) 0.47
Parasite density (>2000/µL) 3.35 1.03–10.10 0.04
Study treatment dosage (mg/
kg for 3 days)
2.10 0.75–5.89 0.16
Risk factors associated with malaria new infection
Treatment
 AL 4.71 3.10–7.15
 MQAS 1.59 1.02–2.46
 DHAPQ 1 1 (reference) <0.01a
Maternal age (15–19 years) 1.78 1.26–2.52 <0.01a
Parasite density (>2000/µL) 1.46 1.09–1.94 0.01
Anaemia (Hb <11.0 g/dL) 1.56 1.05–2.32 0.03
Gravidity
 Primigravidae 1.11 0.80–1.54
 Multigravidae 1 1 (reference) 0.52
Study treatment dosage (mg/kg 
for 3 days)
1.00 0.74–1.37 0.98
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Nevertheless, considering that the post-treatment fol-
low up was up to day 63 and that pregnant women are a 
group particularly difficult to follow, the sample size had 
been estimated assuming a dropout rate of 20%, while 
the actual figure was 16%. Such a relatively high dropout 
rate is unlikely to have had a major influence on the trial’s 
results as the patients excluded and those included did 
not differ significantly on their baseline characteristics.
Conclusions
The study has shown that both AL and DHAPQ were well 
tolerated in second and third trimester pregnant women, 
with low treatment failures. MQAS was less well toler-
ated than the other two treatments though it had similar 
low treatment failure. DHAPQ seems to be well tolerated 
and has low treatment failure with a longer post-treat-
ment prophylaxis. As new infections can be prevented by 
Table 4 Pregnant women with  an adverse event till  63  days having received at  least one malaria treatment dose 
in Nchelenge, Zambia (2010–2014)
AE adverse event; SAE serious adverse event; Related SAE serious adverse event which the investigator classified as possibly, probably or definitely related to study 
drug
a AEs and related AEs recorded in, respectively, at least 10 and 5% of patients in any treatment group
Safety population AL (N = 300) MQAS (N = 299) DHAPQ (N = 300)
At least one AE, n (%) 248 (82.7) 254(84.9) 238 (79.3)
Most common  AEsa, n (%)
 Headache 136 (45.3) 142 (47.5) 134 (44.7)
 Nausea 8 (2.7) 39 (13.0) 23 (7.7)
 Cough 99 (33.0) 116 (38.8) 120 (40.0)
 Asthenia 36 (12.0) 69 (23.1) 49 (16.3)
 Dizziness 11 (3.7) 88 (29.4) 17 (5.7)
 Vomiting 14 (4.7) 47 (15.7) 26 (8.7)
 Abdominal pain 73 (24.3) 71 (23.7) 70 (23.3)
 Musculoskeletal pain 43 (14.3) 47 (15.7) 30 (10.0)
 Backache 51 (17.0) 40 (13.4) 28 (9.3)
 Influenza 24 (8.0) 32 (10.7) 40 (13.3)
At least one related AE, n (%) 54 (18.0) 127 (42.5) 72 (24.0)
Most common related  AEsa, n (%)
 Dizziness 5 (1.7) 72 (24.1) 8 (2.7)
 Nausea 5 (1.7) 34 (11.4) 16 (5.3)
 Vomiting 5 (1.7) 43 (14.4) 17 (5.7)
 Asthenia 9 (3.0) 38 (12.7) 14 (4.7)
 Headache 14 (4.7) 16 (5.4) 15 (5.0)
SAE n (%) 0 4 (1.3) 3 (1.0)
Related SAE, n (%) 0 1 (0.3) 0
At least one SAE which caused death, n (%) 0 1 (0.3) 0
Birth outcomes, n (%)
 Still birth 8 (2.8) 3 (1.1) 10 (3.7)
 Miscarriage 0 (0) 2 (0.7) 1 (0.4)
 Prematurity 13 (4.6) 6 (2.2) 10 (3.7)
 Congenital abnormality 7 (2.6) 4 (1.5) 4 (1.6)
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a long acting partner drug to the artemisinins, DHAPQ 
should be preferred where transmission is intense as in 
Nchelenge while and in areas of low transmission inten-
sity AL or MQAS may be used.
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